Piramal Pharma Falls 3.32%: Four Key Factors Driving This Week’s Decline

16 February 2026: Upgrade to Sell Amid Mixed Signals

On Monday, Piramal Pharma’s rating was upgraded from Strong Sell to Sell by MarketsMOJO, reflecting a nuanced shift in technical outlook despite ongoing financial challenges. The stock closed at ₹164.30, down 0.96% from the previous close, but intraday it showed resilience, closing higher than Friday’s ₹163.15 close. The upgrade was driven by improvements in technical indicators such as a mildly bullish Dow Theory weekly trend and On-Balance Volume (OBV), even as fundamental concerns persisted.

Financially, the company reported negative earnings for three consecutive quarters, with Q3 FY25-26 showing a PBT loss of ₹-95.99 crores and PAT loss of ₹-95.08 crores. Return on Equity remained critically low at 0.32%, while the Debt to EBITDA ratio of 3.83 times highlighted elevated leverage. Despite these headwinds, valuation metrics suggested the stock was trading at a discount relative to peers, supported by strong long-term operating profit growth of 111.53% annually over five years.

Technical Momentum Shifts to Mildly Bearish

Also on 16 February, technical momentum shifted from strongly bearish to mildly bearish. The Moving Average Convergence Divergence (MACD) remained bearish weekly but softened monthly, while the Relative Strength Index (RSI) showed neutral readings. Bollinger Bands indicated mild bearishness, and daily moving averages remained bearish, signalling ongoing downward pressure. The Know Sure Thing (KST) indicator was bearish weekly, but Dow Theory and OBV suggested some underlying strength.

This mixed technical picture was reflected in the stock’s intraday volatility, with a range between ₹159.00 and ₹168.00. The stock remained well below its 52-week high of ₹241.00 but comfortably above its 52-week low of ₹148.30, indicating some support at lower levels.

17 February 2026: Technical Momentum Turns Bearish

On Tuesday, the technical outlook deteriorated further as Piramal Pharma’s momentum shifted from mildly bearish to outright bearish. The stock closed at ₹164.70, up 0.24% intraday but down 0.96% from Monday’s close, reflecting a cautious market response. Daily moving averages turned bearish, and the weekly MACD remained negative. Bollinger Bands signalled bearish conditions on the weekly chart, while the Know Sure Thing (KST) indicator confirmed short-term weakness.

Volume-based indicators such as On-Balance Volume (OBV) showed no clear trend, suggesting a lack of strong conviction behind recent price moves. Dow Theory on the weekly timeframe remained mildly bullish, indicating potential underlying support, but the overall technical signals pointed to increasing downside risk. The stock’s trading range narrowed between ₹163.30 and ₹169.25, maintaining proximity to its 52-week low.

19 February 2026: Downgrade to Strong Sell Amid Weak Financials and Bearish Technicals

By Thursday, MarketsMOJO downgraded Piramal Pharma from Sell to Strong Sell, reflecting worsening fundamentals and intensifying bearish technical signals. The stock closed at ₹162.75, down 2.02% on the day, marking the steepest single-day decline of the week. The downgrade was driven by continued negative earnings, with Q3 FY25-26 losses deepening and profitability metrics deteriorating further.

Return on Capital Employed (ROCE) remained modest at 2.7%, but the Debt to EBITDA ratio of 3.83 times underscored elevated financial risk. The company’s profits contracted by 372.9% over the past year, and the stock underperformed the broader market, declining 15.56% over the last year while the BSE500 index gained 14.27%. Technical indicators such as MACD, Bollinger Bands, and KST all signalled bearish momentum, while daily moving averages confirmed sustained selling pressure.

20 February 2026: Week Closes on a Weak Note

On Friday, the stock closed at ₹160.40, down 1.44% from Thursday’s close, extending the week’s downward trend. The Sensex, in contrast, gained 0.41%, highlighting Piramal Pharma’s continued underperformance. Volume was notably lower at 63,990 shares, suggesting reduced trading interest amid bearish sentiment. Technical indicators remained negative, with no signs of immediate reversal. The stock’s 52-week range of ₹148.30 to ₹241.00 emphasises the significant volatility and challenges faced over the past year.

Key Takeaways

1. Financial Weakness Persists: The company’s third consecutive quarterly losses and poor profitability metrics, including a negative PAT of ₹-95.08 crores and low ROE of 0.32%, continue to weigh heavily on investor sentiment.

2. Technical Indicators Signal Downside Risk: The shift from mildly bearish to outright bearish technical momentum, confirmed by MACD, Bollinger Bands, and KST, suggests further near-term pressure on the stock price.

3. Valuation Discounted but Risky: Despite trading at a discount relative to peers, the subdued sales growth of 7.96% annually and high leverage (Debt to EBITDA of 3.83) temper valuation appeal.

4. Institutional Confidence Remains: A significant 45.35% institutional holding indicates some confidence in the company’s longer-term prospects, though the downgrade to Strong Sell signals caution.

Conclusion

Piramal Pharma Ltd’s week was marked by a clear deterioration in both fundamental and technical conditions, culminating in a downgrade to Strong Sell by MarketsMOJO. The stock’s 3.32% weekly decline contrasted sharply with the Sensex’s modest gains, underscoring the challenges faced by the company amid persistent losses, high leverage, and bearish technical momentum. While valuation metrics suggest some discount relative to peers, the risks remain elevated, and investors should remain cautious given the prevailing negative trends. The sizeable institutional stake may provide some stability, but the overall outlook calls for vigilance as the stock navigates a difficult operating environment.

Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today